EntryPoint Capital LLC Invests $435,000 in Integer Holdings Co. (NYSE:ITGR)

EntryPoint Capital LLC purchased a new position in shares of Integer Holdings Co. (NYSE:ITGR) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 3,280 shares of the medical equipment provider’s stock, valued at approximately $435,000.

Several other large investors have also recently added to or reduced their stakes in ITGR. Mather Group LLC. boosted its holdings in Integer by 304.3% during the fourth quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 143 shares in the last quarter. Lee Danner & Bass Inc. purchased a new stake in shares of Integer during the 4th quarter worth approximately $27,000. R Squared Ltd purchased a new stake in shares of Integer during the 4th quarter worth approximately $44,000. Versant Capital Management Inc increased its stake in Integer by 98.4% in the 4th quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider’s stock valued at $49,000 after purchasing an additional 183 shares in the last quarter. Finally, Principal Securities Inc. raised its holdings in Integer by 31.2% during the fourth quarter. Principal Securities Inc. now owns 639 shares of the medical equipment provider’s stock worth $85,000 after purchasing an additional 152 shares during the last quarter. 99.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on ITGR shares. KeyCorp lifted their price target on Integer from $144.00 to $154.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Citigroup upped their price target on shares of Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a report on Wednesday, December 11th. Oppenheimer lowered shares of Integer from an “outperform” rating to a “market perform” rating in a research report on Friday, February 21st. Benchmark lifted their price objective on Integer from $140.00 to $150.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Finally, Wells Fargo & Company reiterated an “overweight” rating and set a $160.00 target price on shares of Integer in a report on Tuesday, December 3rd. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $149.00.

Integer Price Performance

Integer stock opened at $119.02 on Wednesday. The company has a quick ratio of 2.09, a current ratio of 2.95 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $4.00 billion, a P/E ratio of 35.42, a PEG ratio of 1.72 and a beta of 1.24. The firm has a fifty day moving average of $131.84 and a 200-day moving average of $132.22. Integer Holdings Co. has a 52-week low of $107.11 and a 52-week high of $146.36.

Integer (NYSE:ITGR) last issued its earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share for the quarter, missing the consensus estimate of $1.46 by ($0.03). The company had revenue of $449.50 million during the quarter, compared to analysts’ expectations of $446.28 million. Integer had a return on equity of 11.65% and a net margin of 6.92%. As a group, analysts predict that Integer Holdings Co. will post 6.01 EPS for the current year.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.